TY - JOUR
T1 - Systemic treatment in advanced phyllodes tumor of the breast
T2 - a multi-institutional European retrospective case-series analyses
AU - Palassini, E.
AU - Mir, O.
AU - Grignani, G.
AU - Vincenzi, B.
AU - Gelderblom, H.
AU - Sebio, A.
AU - Valverde, C.
AU - Baldi, G. G.
AU - Brunello, A.
AU - Cardellino, G. G.
AU - Marrari, A.
AU - Badalamenti, G.
AU - Martin-Broto, J.
AU - Ferraresi, V.
AU - Libertini, M.
AU - Turano, S.
AU - Gataa, I.
AU - Collini, P.
AU - Tos, A. P.Dei
AU - Gennaro, M.
AU - Bini, F.
AU - Provenzano, S.
AU - Vullo, S. Lo
AU - Mariani, L.
AU - Le Cesne, A.
AU - Casali, P. G.
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Background: We aimed at investigating outcome of systemic treatments in advanced breast PT. Methods: All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centers involved in the study, were retrospectively reviewed. Results: 56 female patients were identified. Median age was 52 (range of 25–76) years. Patients received a median number of 2 systemic treatments (range of 1–4). Best responses according to RECIST were 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high-dose ifosfamide given as a continuous infusion (HD-IFX); 3 (20.0%) SD, 12 (80.0%) PD with a gemcitabine-based regimen (with 2 patients not evaluable); 1 (8.3%) PR, 2 (16.7%) SD, 9 (75.0%) PD with trabectedin (with 1 patient not evaluable); 1 (16.7%) PR, 1 (16.7%) SD, 4 (66.7%) PD with tyrosine-kinase inhibitors (TKI). The median PFS were 5.7 (IQR 2.5–9.1) months with AI; 3.2 (IQR 2.2–5.0) months with anthracycline alone; 3.4 (IQR 1.4–6.7) months with HD-IFX; 2.1 (IQR 1.4–5.2) months with gemcitabine-based chemotherapy; 1.8 (IQR 0.7–6.6) months with trabectedin; 3.4 (IQR 3.1–3.8) months with TKI. With a median follow-up of 35.3 (IQR 17.6–66.9) months, OS from the start of first-line systemic treatment was 15.2 (IQR 7.6–39.6) months. Conclusion: In this series of advanced PT (to our knowledge, the largest reported so far), AI was associated with a high rate of responses, however, with a median PFS of 5.7 months. Other systemic treatments were poorly active.
AB - Background: We aimed at investigating outcome of systemic treatments in advanced breast PT. Methods: All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centers involved in the study, were retrospectively reviewed. Results: 56 female patients were identified. Median age was 52 (range of 25–76) years. Patients received a median number of 2 systemic treatments (range of 1–4). Best responses according to RECIST were 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high-dose ifosfamide given as a continuous infusion (HD-IFX); 3 (20.0%) SD, 12 (80.0%) PD with a gemcitabine-based regimen (with 2 patients not evaluable); 1 (8.3%) PR, 2 (16.7%) SD, 9 (75.0%) PD with trabectedin (with 1 patient not evaluable); 1 (16.7%) PR, 1 (16.7%) SD, 4 (66.7%) PD with tyrosine-kinase inhibitors (TKI). The median PFS were 5.7 (IQR 2.5–9.1) months with AI; 3.2 (IQR 2.2–5.0) months with anthracycline alone; 3.4 (IQR 1.4–6.7) months with HD-IFX; 2.1 (IQR 1.4–5.2) months with gemcitabine-based chemotherapy; 1.8 (IQR 0.7–6.6) months with trabectedin; 3.4 (IQR 3.1–3.8) months with TKI. With a median follow-up of 35.3 (IQR 17.6–66.9) months, OS from the start of first-line systemic treatment was 15.2 (IQR 7.6–39.6) months. Conclusion: In this series of advanced PT (to our knowledge, the largest reported so far), AI was associated with a high rate of responses, however, with a median PFS of 5.7 months. Other systemic treatments were poorly active.
KW - Advanced setting
KW - Breast tumor
KW - Chemotherapy
KW - Phyllodes
KW - Sarcoma
UR - http://www.scopus.com/inward/record.url?scp=85124708470&partnerID=8YFLogxK
U2 - 10.1007/s10549-022-06524-4
DO - 10.1007/s10549-022-06524-4
M3 - Article
C2 - 35150367
AN - SCOPUS:85124708470
SN - 0167-6806
VL - 192
SP - 603
EP - 610
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -